Online inquiry

IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8553MR)

This product GTTS-WQ8553MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD4 gene. The antibody can be applied in AIDS research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000616.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 920
UniProt ID P01730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8553MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1786MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ3180MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ13569MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ6671MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ6283MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ3508MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ8731MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ1763MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW